Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. announced that the resolution proposed at their extraordinary general meeting was successfully passed. The resolution involved the approval of terms and transactions under a Disposal Agreement, which was unanimously supported by shareholders who attended the meeting. This development signifies a strategic move for the company, potentially impacting its operational focus and market positioning.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on the development and commercialization of innovative medical devices, particularly those related to cardiovascular health.
Average Trading Volume: 2,703,183
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.01B
See more data about 2500 stock on TipRanks’ Stock Analysis page.